- Bufotaline
-
- $0.00 / 20mg
-
2023-02-24
- CAS:471-95-4
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- Bufotaline
-
- $350.00 / 10KG
-
2019-07-06
- CAS:471-95-4
- Min. Order: 1KG
- Purity: 99.5%
- Supply Ability: 10000kg
|
| | Bufotaline Basic information |
| Product Name: | Bufotaline | | Synonyms: | 3-BETA-14,16-BETA-TRIHYDROXY-5BETA-BUFA-20,22-DIENOLIDE SULFATE;16-(Acetyloxy)-3,14-dihydroxybufa-20,22-dienolide;22-dienolide,3-beta,14,16-beta-trihydroxy-5-beta-bufa-216-acetate;5beta-Bufa-20,22-dienolide, 3beta,14,16beta-trihydroxy-, 16-acetate;Bufa-20,22-dienolide, 16-(acetyloxy)-3,14-dihydroxy-, (3beta,5beta,16beta)-;Bufotaline;BUFOTALIN;BUFOTALIN SULFATE | | CAS: | 471-95-4 | | MF: | C26H36O6 | | MW: | 444.56 | | EINECS: | | | Product Categories: | Miscellaneous Natural Products | | Mol File: | 471-95-4.mol |  |
| | Bufotaline Chemical Properties |
| Melting point | 223°C (rough estimate) | | alpha | D20 +5.4° (c = 0.5 in chloroform) | | Boiling point | 474.53°C (rough estimate) | | density | 1.0942 (rough estimate) | | refractive index | 1.4593 (estimate) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml | | form | White to off-white solid. | | pka | 14.44±0.70(Predicted) | | color | White to off-white | | CAS DataBase Reference | 471-95-4 | | NIST Chemistry Reference | Bufotalin(471-95-4) |
| RIDADR | 3172 | | HazardClass | 6.1(a) | | PackingGroup | II | | HS Code | 29329990 |
| | Bufotaline Usage And Synthesis |
| Chemical Properties | Crystalline genin. | | Uses | Bufotalin is a component of Bufo bufo gargarizans which acts as an anti-tumor agent. | | Definition | ChEBI: Bufotalin is a steroid lactone. It is functionally related to a bufanolide. | | Hazard | Deadly poison. | | in vivo | Bufotalin (0.5-1 mg/kg; intraperitoneal injection; twice daily; for 7 days) treatment shows a significantly reduced tumor growth in mice[1]. | Animal Model: | SCID male mice (4-6 weeks old) injected with U2OS cells[1] | | Dosage: | 0.5 mg/kg, 1 mg/kg | | Administration: | Intraperitoneal injection; twice daily; for 7 days | | Result: | Inhibited U2OS osteoblastoma cell growth in mice. |
|
| | Bufotaline Preparation Products And Raw materials |
|